Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A New Chemiluminescent Enzyme Immunoassay for Plasma Tissue Factor Detection

Yuki Fujiwara1,2, Yoshikatsu Koga1, Kimiko Hasegawa3, Hiroya Fujii3, Tetsuji Yamaguchi3, Ryou Tsumura1,2, Masahiro Yasunaga1and Yasuhiro Matsumura1,2*

1Division of Developmental Therapeutics, Research Centre for Innovative Oncology, National Cancer Centre Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan

2Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa, Chiba, Japan

3JSR Life Sciences, R&D Department Unit 1, 25 Miyukigaoka, Tsukuba, Ibaraki, Japan

Corresponding Author:
Yasuhiro Matsumura
Division of Developmental Therapeutics
Research Centre for Innovative Oncology
National Cancer Centre Hospital East
6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
Tel: 04- 7134-6857
E-mail: yhmatsum@east.ncc.go.jp

Received Date: October 23, 2014; Accepted Date: November 26, 2014; Published Date: December 03, 2014

Citation: Fujiwara Y, Koga Y, Hasegawa K, Fujii H, Yamaguchi T, et al. (2014) A New Chemiluminescent Enzyme Immunoassay for Plasma Tissue Factor Detection. Biosens J 3:111. doi: 10.4172/2090-4967.1000111

Copyright: © 2014 Fujiwara Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

High concentrations of tissue factor (TF) in the plasma may have a major role in the elevated risk of thrombosis in patients with malignant diseases. The quantification of plasma TF concentrations in cancer patients may enable accurate assessments of the risk of thrombosis during the process of cancer progression. Whether the plasma TF concentration is associated with the tumor volume in pancreatic cancer in the field of cancer biology remains uncertain. Rat anti-human TF monoclonal antibodies were prepared in our laboratory and were used in a chemiluminescent enzyme immunoassay (CLEIA) for TF detection. In an in vitro experiment, the antibodies for human TF did not crossreact with mouse TF. Therefore, tumor-derived TF was specifically detected using a novel sensitive human TF detection system developed for this study. The plasma concentration of tumor-derived TF was positively correlated with the tumor volume in mice bearing the human pancreatic cancer cell line BxPC-3. Thus, the plasma TF concentration may be a useful tumor marker. These data warrant further preclinical and clinical investigations of our CLEIA system.

Keywords

Top